ストックスクリーナーアプリを入手
1.36
2.16%
-0.03
Tiziana Life Sciences Ltd (TLSA) 最新ニュース
Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease - BioSpace
Small cap wrap: Lancaster Resources, Cerro de Pasco, Tiziana Life Sciences, Nano One Materials... - Proactive Investors
Tiziana reports reduction in microglial activation in Alzheimer’s case treated with nasal foralumab - Proactive financial news
TLSA: Tiziana Life Sciences Study Shows Promise for Alzheimer's Treatment | TLSA Stock News - GuruFocus
Journal Of Clinical Nuclear Medicine Publishes Results Of Tiziana’S Nasal Foralumab In Study Treating Moderate Alzheimer's Disease - MENAFN.com
Journal of Clinical Nuclear Medicine Publishes Results of - GlobeNewswire
Revolutionary Nasal Treatment Reduces Brain Inflammation in Moderate Alzheimer's Patient, Harvard Study Shows - Stock Titan
Tiziana Life Sciences chairman increases stake to over 37% - Proactive financial news
Executive Chairman Increases Stake in Tiziana Life Sciences (TLS - GuruFocus
Tiziana Life Sciences Announces Purchase of Shares by Chairman - The Manila Times
Tiziana reports promising Alzheimer’s treatment results By Investing.com - Investing.com Nigeria
Tiziana reports promising Alzheimer’s treatment results - Investing.com
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab - BioSpace
Tiziana Reports PET data sees reduced neuroinflammation in patient treated with Intranasal Therapy - Proactive Investors
Market movers: Lyft, US Gold, Tiziana Life Sciences... - Proactive financial news
Tiziana Life Sciences reports reduced brain inflammation in Alzheimer’s patient treated with nasal foralumab - Proactive Investors
TLSA: Tiziana Life Sciences Reports Positive PET Scan Results in Alzheimer's Treatment | TLSA Stock News - GuruFocus
Tiziana stock gains on data for Alzheimer's drug (TLSA:NASDAQ) - Seeking Alpha
Tiziana Life Sciences Announces Significant Reduction In Microglia Activation In PET Scan Of Moderate Alzheimer's Patient Treated With Intranasal Foralumab - MENAFN.com
Tiziana Life Sciences Announces Significant Reduction in - GlobeNewswire
Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study - PMLiVE
Small cap wrap: Tiziana Life Sciences, Millennial Potash, Century LIthium... - Proactive financial news
Tiziana shares surge 21% on promising multiple sclerosis data - Proactive financial news
Tiziana rises on positive results in multiple sclerosis treatment study - Seeking Alpha
Tiziana reports encouraging results for nasal MS drug in early study - Proactive financial news
TLSA's Nasal Foralumab Shows Promise in MS Treatment Study | TLS - GuruFocus
TLSA's Nasal Foralumab Shows Promise in MS Treatment Study | TLSA Stock News - GuruFocus
Clinical Trial Success: Revolutionary Nasal Spray Halts Multiple Sclerosis Progression in Landmark Study - Stock Titan
Tiziana shares surge on encouraging results for nasal MS drug in early study - Proactive financial news
Geode Capital Management LLC Raises Stock Holdings in Tiziana Life Sciences Ltd (NASDAQ:TLSA) - Defense World
Tiziana Life Sciences Delays Annual Report Filing - TipRanks
Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025 - Insider Monkey
Why These 15 Healthcare Stocks Are Surging in 2025 - Insider Monkey
Dosing begins in Tiziana Life Sciences’ trial of foralumab for na-SPMS - Yahoo Finance
How to interpret Tiziana Life Sciences Ltd (TLSA)’s stock chart patterns - uspostnews.com
Tiziana Life Sciences Ltd: A Comprehensive Look at the Stock’s Ups and Downs - investchronicle.com
Small cap wrap: Tiziana Life Sciences, Excellon Resources, Lancaster Resources... - Proactive financial news
Tiziana Life Sciences Announces University of Massachusetts Starts Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial - marketscreener.com
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial - The Manila Times
Breakthrough MS Treatment Trial: UMass Joins Harvard, Yale, Johns Hopkins Testing Home-Use Nasal Drug - Stock Titan
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2… - Informazione.it
Tiziana Life Sciences announces patient dosing in Phase 2 MS trial - Proactive Investors
Multiple sclerosis Pipeline Analysis and Clinical Trials - openPR.com
TLSATiziana Life Sciences Ltd Com Latest Stock News & Market Updates - Stock Titan
Small cap wrap: Zero Candida, Midnight Sun Mining, Tiziana Life Sciences, Trust Stamp... - Proactive financial news
Tiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns Hopkins - Proactive financial news
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab In Phase 2 Multiple Sclerosis Clinical Trial - MarketScreener
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial - The Manila Times
Major Breakthrough: Johns Hopkins Launches Novel Nasal Treatment in Phase 2 MS Trial - Stock Titan
Tiziana Life Sciences' lead candidate demonstrates favorable safety profile and clinical response - Proactive Investors
Tiziana Life Sciences begins dosing in trial of therapy for multiple sclerosis - Yahoo Finance
Small cap wrap: Northern Superior Resources, Tiziana Life Sciences, Alternus Clean Energy... - Proactive Investors
Multiple sclerosis Clinical Trials and Studies 2025: EMA, PDMA, - openPR
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):